| Literature DB >> 34837917 |
Manikantan Pappuswamy1, Arun Meyyazhagan1, Balamuralikrishnan Balasubramanian2, Haripriya Kuchi Bhotla3, Karthika Pushparaj4, Murugesh Eswaran5, Vijaya Anand Arumugam6, Thirunavukkarasu Periyaswamy7, Aditi Chaudhary1, Nanditha Rajesh1, Rajkumar Sundaram8, Karthick Dhandapani3.
Abstract
BACKGROUND: Cooking oil fumes (COFs) with smoking habits is a substantial risk that aggravates genetic modifications. The current study was to estimate the biological markers of genetic toxicity counting Micronucleus changes (MN), Chromosome Aberrations (CA) and DNA modifications among COFs exposures and control subjects inherent from South India.Entities:
Keywords: Comet; Cytogenetic changes; DNA; Tobacco user; cooking oil fumes
Mesh:
Substances:
Year: 2021 PMID: 34837917 PMCID: PMC9068188 DOI: 10.31557/APJCP.2021.22.11.3591
Source DB: PubMed Journal: Asian Pac J Cancer Prev ISSN: 1513-7368
Demographic Details of Age and Year of Exposure and Risk Factors in Tobacco Users
| Particulars | No. of sample | Year of exposure | Age | BP (%) | Diabetes | Spontaneous | Cardiac |
|---|---|---|---|---|---|---|---|
| Total Experimentals | 212 | 10.63 ± 4.86 | 42.69 ± 14.67 | 33 (15.56) | 23 (10.84) | 7 (3.30) | 5 (2.35) |
| Male | 93 (43.86) | 11.63 ± 5.83 | 41.44 ± 15.12 | 11 (11.82) | 10 (10.75) | 3 (3.22) | |
| Female | 119 (55.66) | 10.21 ± 4.19 | 43.39 ± 14.40 | 12 (10.08) | 13 (10.92) | 7 (5.88) | 2 (1.68) |
| Controls | |||||||
| Group I | 84 (39.62) | 31.19 ±7.46 | 1 (1.19) | ||||
| Male | 37 (44.04) | 28.63 ± 5.68 | |||||
| Female | 47 (55.95) | 32.23 ± 8.18 | 1 (2.12) | ||||
| Group II | 128(60.37) | 52.22 ± 7.47 | 4 (3.12) | 4 (3.12) | |||
| Male | 56 (43.75) | 54.25 ± 9.32 | 2 (3.57) | 2 (3.57) | |||
| Female | 72 (56.25) | 52.70 ± 8.01 | 2 (2.77) | 2 (2.77) | |||
| Experimental | |||||||
| Group I | 84 (39.62) | 6.15 ± 0.75 | 29.20 ± 5.49 | 3 (3.57) | 5 (5.95) | 09 (10.71) | |
| Male | 37 (44.04) | 5.48 ± 1.20 | 26.79 ± 5.63 | 1 (2.70) | 2 (5.40) | ||
| Female | 47 (55.95) | 6.46 ± 1.69 | 31.54 ± 4.87 | 2 (4.25) | 3 (6.38) | 09 (19.14) | |
| Group II | 128(60.37) | 15.56 ± 3.56 | 52.45 ± 12.38 | 22 (17.18)* | 17 (8.01) | 4 (03.12) | |
| Male | 56 (43.75) | 16.03 ± 4.61 | 50.42 ± 12.38 | 12 (21.48) | 8 (14.28) | 3(5.35) | |
| Female | 72 (56.25) | 13.60 ± 3.10 | 53.43 ± 12.51 | 10 (13.88) | 09 (12.50) | 1 (1.38) | |
| Between | 212 | ||||||
| Smokers | 53 (25.00) | 10.74 ± 5.89 | 34.67 ± 13.81 | 2(3.77) | 2(3.77) | ||
| SL tobacco users | 104 (49.05) | 11.23 ± 4.29 | 40.85 ± 13.09 | 06 (5.76) | 6 (5.76) | 3 (2.88) | |
| Smokers and | 55 (25.94) | 13.86 ± 4.49 | 58.55 ± 09.54 | 15 (27.27)* | 05(09.09) | 1(1.81) |
SD, standard deviation; FS, Female subjects; RR, Reference range; *, Significantly higher when compared to the other groups.
Frequencies of Micronuclei Scored in Buccal and Blood Cells of Tobacco Users and Controls
| Particulars | No. of | Mean frequency of | Mean frequency of | Blood | Buccal |
|---|---|---|---|---|---|
| Controls | |||||
| Group I | 84 | 0.69 ± 0.54 | 0.65 ± 0.58 | ||
| Male | 37 | 0.71 ± 0.57 | 0.58 ± 0.58 | 0.003 | |
| Female | 47 | 0.53 ± 0.52 | 0.73± 0.62 | 0.021 | |
| Group II | 128 | 1.09 ± 0.56 | 1.18 ± 0.71 | 0.001 | 0.34 |
| Male | 56 | 1.14 ± 0.58 | 1.12 ± 0.65 | ||
| Female | 72 | 1.09 ± 0.56 | 1.12 ± 0.74 | 0.002 | |
| Experimental | |||||
| Group I | 84 | 1.64 ± 0.87 | 2.08 ± 1.31* | 0.001 | |
| Male | 37 | 1.76 ± 0.65 | 2.35 ± 1.38 | 0.001 | |
| Female | 47 | 1.65 ± 0.96 | 2.05 ± 1.42 | 0.703 | |
| Group II | 128 | 2.37 ± 0.67# | 3.15 ± 1.27* | 0.001# | |
| Male | 56 | 2.54 ± 0.71** | 2.85 ± 1.39 | 0.002 | 0.001 |
| Female | 72 | 2.21 ± 0.80 | 2.56 ± 1.35 | ||
| Between Experimentals | 212 | ||||
| Smokers | 53 | 2.11 ± 0.72 | 2.86 ± 1.46 | 0.002 | |
| SLT users | 104 | 2.21 ± 0.87 | 2.42 ± 1.23 | ||
| Smokers and SLT users | 55 | 2.50 ± 0.82a | 2.68 ± 1.53 | 0.002 | 0.001 |
*, #, Significantly elevated when compared to controls subjects as estimated by ANOVA; **, Significantly elevated compared to controls and group I and female experimental subjects. A Significantly elevated compared to controls and smokers experimental subject as estimated by ANOVA followed by Bonferroni’s correction for multiple comparisons.
Figure 1Represent the Frequencies of Micronuclei in Buccal and Blood Cells of COFs Exposures and Controls. Blood MN Level was Elevated when Compared to the Controls and Other Subjects
Figure 2Shows the Chromosome Alterations in Controls and Experimental Subjects
Frequencies of Comets Scored in Blood Cells of Tobacco Users and Controls
| Subjects | Number of | Tail length (TL) | Tail moment (TM) |
|---|---|---|---|
| Controls | |||
| Group I | 84 | 1.36 ± 1.15 | 1.23 ± 0.65 |
| Male | 37 | 1.20 ± 0.82 | 1.23 ± 0.72 |
| Female | 47 | 1.25 ± 1.23 | 1.21 ± 0.63 |
| Group II | 128 | 1.53 ± 1.42 | 1.31 ± 1.08 |
| Male | 56 | 1.74 ± 1.01# | 1.67 ± 1.26a |
| Female | 72 | 1.37 ± 0.78 | 1.12 ± 1.93 |
| Experimental | |||
| Group I | 84 | 3.25 ± 1.25 | 2.51 ± 1.27 |
| Male | 37 | 3.35 ± 1.24 | 2.47 ± 1.50 |
| Female | 47 | 3.12 ± 1.24 | 2.53 ± 1.17 |
| Group II | 128 | 4.24 ± 1.43* | 2.85 ± 1.32 |
| Male | 56 | 4.15 ± 1.52 | 3.64 ± 0.34 |
| Female | 72 | 4.37 ± 1.46# | 2.77 ± 0.52 |
| Between | 212 | ||
| Smokers | 53 | 3.52 ± 1.46 | 2.61 ± 1.42 |
| SLT users | 104 | 3.62 ± 1.54 | 2.57 ± 1.14 |
| Smokers and SLT users | 55 | 4.37 ± 1.13** | 3.36 ± 1.49 |
*p < 0.001 level significantly; elevated compared to controls groups. #Significantly elevated when compared to controls and group I; experimental male and female subject. **, Significantly elevated when compared to controls and smokers and SLT; experimental subject as estimated by ANOVA followed by Bonferroni’s correction for multiple comparisons.
Figure 3Demonstration of Comets Scored in Blood Cells of COFs Exposures and Controls
Frequencies of Chromosome Aberrations in Smokeless Tobacco Users and Controls
| Subjects | Number | Chromosome aberrations | Chromatid- type aberrations | Chromosome type aberration | |
|---|---|---|---|---|---|
| Chromatid- type | Chromosome-type | ||||
| Controls | |||||
| Group I | 84 | 0.60 ± 0.77 | 0.43 ± 0.40 | ||
| Male | 37 | 0.58 ± 0.68 | 0.42 ± 0.41 | 0.324 | 1 |
| Female | 47 | 0.67 ± 0.78 | 0.46± 0.43 | ||
| Group II | 128 | 0.87 ± 0.60 | 0.65 ± 0.60 | ||
| Male | 56 | 1.04 ± 0.65 | 0.68 ± 0.76 | 0.02 | |
| Female | 72 | 0.86 ± 0.61 | 0.62 ± 0.57 | 0.042 | 0.801 |
| Experimental | |||||
| Group I | 84 | 1.57 ± 0.84 | 0.72 ± 0.64 | ||
| Male | 37 | 1.52 ± 0.85 | 0.65 ± 0.72 | 0.001 | |
| Female | 47 | 1.61 ± 0.80 | 0.73 ± 0.64 | 0.325 | |
| Group II | 128 | 2.28 ± 1.21# | 1.32 ± 1.15 | 0.002 | |
| Male | 56 | 2.36 ± 1.09 | 1.48 ± 0.86 | ||
| Female | 72 | 2.20 ± 1.08 | 1.29 ± 1.28 | 0.002 | 0.324 |
| Between Experimentals | 212 | ||||
| Smokers | 53 | 1.82 ± 1.03 | 1.03 ± 0.83 | ||
| SLT users | 104 | 2.22 ± 1.42 | 1.23 ± 1.31 | 0.001 | |
| Smokers and SLT users | 55 | 2.43 ± 1.28*a | 1.45 ± 0.84*a | 0.001 | |
*, Significantly elevated when compared to the controls and smokers’ subjects as estimated by ANOVA; #, Significantly elevated compared to the group I subjects; a, Significantly elevated when compared to controls and smokers experimental subject as estimated by ANOVA followed by Bonferroni’s correction for multiple comparisons.